Mae'r cynnwys hwn ar gael yn Saesneg yn unig.
We will continue to contribute to the University's research record in terms of quality and impact on the world stage.
Yangzheng Xiaoji as a metastasis inhibitor
Our team, colleagues at Peking University and Yiling Group have together tested the health benefits of the Chinese herbal medicine Yangzheng Xiaoji. The herbal formula had previously been shown to be beneficial to cancer patients, but until this latest research, the way in which it worked had remained unknown.
The research collaboration investigated how the formula works and discovered that it blocks a pathway involved in reducing the spread of cancer cells around the body. The Chinese formula has been shown to be beneficial to patients with certain solid tumours when used alone and in particular when used as an adjuvant treatment alongside conventional therapies such as chemotherapy.
Seven of our externally funded joint research projects have led to the discovery of new biomarkers for breast, prostate and kidney cancer. These markers have been independently validated in the UK and China for their long-term clinical relevance to the patients.
Recognition and awards
- Outstanding Contribution to International Work, Medic Star Award, Cardiff University, October 2017.
- China-UK Cancer Research International Collaboration Base (Beijing) with CMU in April 2014
- Key Laboratories of Cancer Invasion and Metastasis with CMU awarded by the Beijing Government in June 2014
- Outstanding Achievement Award for research on novel approaches in treating transcoelomic metastasis of cancers in the abdomen, awarded by the World of Oncology, Athens in October 2014
- TIMES Higher Education ‘International Collaboration of the Year’ award 2011.